Debates in allergy medicine: Specific immunotherapy in children with atopic dermatitis, the "con" view. by Ginsberg, David N & Eichenfield, Lawrence F
UC San Diego
UC San Diego Previously Published Works
Title
Debates in allergy medicine: Specific immunotherapy in children with atopic dermatitis, 
the "con" view.
Permalink
https://escholarship.org/uc/item/73d514rt
Journal
The World Allergy Organization journal, 9(1)
ISSN
1939-4551
Authors
Ginsberg, David N
Eichenfield, Lawrence F
Publication Date
2016
DOI
10.1186/s40413-016-0107-2
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
DEBATE Open Access
Debates in allergy medicine: Specific
immunotherapy in children with atopic
dermatitis, the “con” view
David N. Ginsberg1 and Lawrence F. Eichenfield2,3*
Please see related Debate article: Debates in allergy medicine: specific immunotherapy efficiency in children with atopic dermatitis,
http://dx.doi.org/10.1186/s40413-016-0106-3
Abstract
Atopic dermatitis (AD) is a common chronic skin condition in children that has a proven association with other atopic
conditions and allergies. These associations, like the general pathophysiology of AD, are complex and not fully understood.
While there is evidence for the efficacy of specific immunotherapy (SIT) in pediatric asthma and allergic rhinitis (AR), there is
a lack of strong data to support its use in AD. IgE has been shown to be elevated in many patients with AD, but it is an
unreliable biomarker due to variability and great fluctuation over time, poor positive predictive value for clinically relevant
allergy, and poor correlation with disease state. In spite of this, almost all studies of SIT use either positive skin prick testing
(SPT) or serum specific IgE levels to guide therapy. Allergen avoidance, with some exceptions, is generally not effective at
controlling AD in children. The few studies that have investigated the efficacy of SIT in children with AD have produced
conflicting results, and a lack of reproducibility with a standard treatment protocol. Limited studies have shown clinical
improvement in mild to moderate AD cases, but no effect on more severe patients. Uncontrolled studies are difficult to
interpret, due to the natural history of remission or “outgrowing” of AD over time in many patients without specific
interventions. Drawbacks to SIT include the length of treatment, poor compliance, cost, and potential side effect profile. The
potential for misdirection of time and energy away from skin directed therapy could negatively impact on AD outcomes.
Keywords: Specific immunotherapy, Pediatric, Atopic dermatitis, Food allergy, Environmental allergy
Background
Atopic dermatitis (AD) is one of the most common chronic
inflammatory skin conditions of children. The pathophysi-
ology is complex and multifactorial, and is still not fully
understood. There is work showing that epithelial barrier
dysfunction, such as filaggrin deficiencies, may be genetically
mediated and are important risk factors for the development
of AD and other atopic phenomena, including food allergy
(FA) and asthma [1–3]. Increasing insight into the immun-
ology of AD has expanded our understanding of the role of
TH2 responses in AD, which may be strongly influenced by
antigenic challenges [4]. Specific immunotherapy (SIT), di-
rected at these immunologic responses, however, has not
been shown to be a successful, long term treatment modality
in children with AD, despite being clinically useful in allergic
rhinitis (AR) and asthma [5].
Problems with the assumption of casual association
between sensitization to allergen and AD
Historically, many experts have divided AD into intrinsic
and extrinsic. The concept of extrinsic AD is that some
patients throughout the course of their AD are more af-
fected by allergens, but interpretation of these labels is
made uncertain by the data that shows that IgE
sensitization may be present in many individuals without
apparent clinical consequence [6]. While in other cases
the IgE sensitization is associated with clinically signifi-
cant allergies along a broad set of atopic manifestations,
which includes urticarial, eczematous dermatitis, wheez-
ing, proctocolitis, vomiting and AR [7].
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For many patients AD is well known to be the first step
of what is known as the atopic march, which includes AR
and asthma [8]. Current literature shows that children
with AD have an increased prevalence of atopy, or the
tendency toward allergen induced IgE sensitivity, com-
pared to the general pediatric population [9]. However,
this association has proven to be quite complex and diffi-
cult to interpret, given the already complex pathophysi-
ology of AD itself. A review of atopy in AD patients,
focusing mostly on children, showed that the prevalence
of atopy varied from 7–78 % across the literature, with a
higher rate in hospitalized patients, who presumably had
more severe diseases [9]. This large range makes it diffi-
cult to recommend the use of any treatment targeted spe-
cifically at the IgE immune response, when it is possible
that so few patients within a given population would bene-
fit from it. A further issue with many of the reviewed stud-
ies was the sole use of either specific serum IgE or skin
prick testing (SPT) as the only confirmatory test for
sensitization. This likely led to high false positive rates, or
varying rates of positive tests without clinically relevant al-
lergic responses. Studies have shown that, particularly in
young children due to their developing immune system,
each of these tests alone can be difficult to interpret and
they can yield false results [10]. The positive predictive
value (PPV) of SPT alone is less than 40 % when evaluat-
ing FA in AD patients and the specificity of SPT alone for
environmental allergens is between 44–53 % [11, 12]. A
recent review has also shown that there is a surprising lack
of standardization of the practice of SPT by medical pro-
fessionals, despite this technique having been used for
over a century. This gives even more reason to question
the validity of the research using SPT alone [13].
The currently held belief is that a diagnosis of
sensitization with increased IgE response without any
clinical manifestations is not clinically useful. Multiple
studies have shown a trend of increasing total and spe-
cific IgE levels in more severe disease [9, 14]. However,
one of the few studies done on the efficacy of immuno-
therapy in the pediatric AD population did show im-
provement but the only significant results were seen in
the mild to moderate cases, with no clinical improve-
ment seen in severe cases [15].
Although IgE may have an association with AD sever-
ity, using it as a marker for success of treatment with
immunotherapy has not proven effective [16, 17]. IgE
levels have been shown to fluctuate tremendously
throughout childhood, especially in the first year of life,
when they fluctuate due to environmental and maternal
factors [18].
In one of the larger, multi-national, studies done spe-
cifically looking at sensitivities of infants with AD, Bene-
dictis et al. showed that over half of the infants studied
were sensitized to at least one common allergen [19].
They used serum specific IgE to test for sensitization;
the data shows that less than 20 % of the infants with
AD were monosensitized, or had a response to only one
of the common allergens tested, and 36.8 % were poly-
sensitized [19]. The practicality of a more generalized im-
munotherapy could be very different from the currently
used SIT due to the low PPV of skin prick and serum IgE
testing and the uncertainty of their positive results.
Association between food allergy and AD
High rates of serum specific IgEs and positive SPT have
been seen in AD patients and these levels appear to
trend upward with increasing disease severity [16, 17].
Due to high rates of false positive testing, definitions of
FA now require consistent clinical manifestations with
food exposure to make a diagnosis, similarly, in individ-
uals with AD, diagnosis of a FA should require consist-
ent clinical response with food exposure, that may be
eczematous dermatitis or other atopic manifestations.
While numerous studies have documented eczema re-
currence or flares during oral food challenges, the evi-
dence is mixed about the impact of avoidance of FA on
the course of AD [20–22]. This can be rather complex
due to the uncertainty of possible significant late reac-
tions, which are harder to observe and control in clinical
circumstances.
Children with AD often outgrow their disease [23].
Thus it may be hard to know if improvement of AD in
an individual is due to the natural disease progression or
the effect of allergen avoidance. The objective evidence
has not shown clinical utility of food restriction, other
than egg, in children who had proven FA and AD [20].
An important study that may have a potential impact
on the perspectives on FA and AD is the Learning Early
About Peanut Allergy (LEAP) study that enrolled infants
with either severe AD or egg allergy [24]. They per-
formed SPT, enrolling patients with negative tests, or
positive but less than 5 mm wheal size, into randomized
groups. Within each of these groups, half of the patients
were fed peanut products 3 times per week beginning
early in life, and the other half had peanut products
withheld entirely. In both of the groups that were fed
peanuts, there was a marked reduction in the rates of
clinical peanut allergy. Interestingly, in the LEAP study
group there was no apparent impact or change in the
AD time to resolution or eczema severity in the group
that avoided peanuts, compared to those that had early
exposure. Overall there was a poor correlation between
specific IgE, skin prick testing, and the development of
FA. This data does not support the avoidance of food in
the context of patients who may be sensitized. While
peanut allergy was prevented in many individuals, it did
not show improvement of the eczema with this experi-
mental allergen avoidance.
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FAs in general have been shown to affect younger chil-
dren more commonly, while environmental allergies are
more common in adolescents and adults [25]. The re-
ported prevalence of FAs among the AD population is
about 15 %, which is three times higher than the rate
among the general pediatric population [26, 27]. One of
the few studies that assessed for FA in children with AD
that was not hindered by selection bias, and included pa-
tients with a low suspicion of FA, found a prevalence of
30 % [28]. Close to 90 % of these FAs are to egg, milk,
soy, nuts, or wheat.
Both FA and AD have been shown to improve spon-
taneously throughout childhood. Hence, any type of SIT
based on FA would be controversial because it is difficult
to predict the potential progression of the disease at a
young age, and given the extensive length of treatment
required for SIT, with the most commonly accepted dur-
ation being 1–3 years, it might be more prudent to ob-
serve and treat with more conservative management in
early childhood [29].
Previous studies on the clinical efficacy of allergen-specific
immunotherapy for children with AD
Immunotherapy as a treatment for FA is currently under
investigation. The results, though promising, have been
shown through meta-analysis to be insufficient to fully
assess the efficacy of this treatment as acceptable [30].
There have not been studies assessing AD as a sole aller-
gic disorder, as oral immunotherapy studies have been
carried out in both children and adults with multiple
symptoms including anaphylaxis, asthma, generalized
urticaria, and AD. There has also not been an investiga-
tion into whether immunotherapy directed at FA in chil-
dren has any effect on their AD. The current expert
consensus for food allergen testing in children with AD,
is to test only if there is reason for suspicion [31]. This
could include AD that persists in spite of optimized
management and topical therapy, or a history of imme-
diate reaction after ingestion of a specific food [31]. This
same expert panel does not recommend immunotherapy
as a treatment for FA.
Environmental allergens are thought by many to play
an even larger role in AD pathophysiology than food al-
lergens. The current research linking filaggrin mutations
and the associated epithelial defects with AD are helping
to support this belief [3]. This may have led to a greater
focus on the research of SIT directed at environmental
allergens for children with AD. There is also convincing
evidence that clearly link controlled aeroallergen expos-
ure to AD exacerbations [32]. This particular study was
done in adult patients with grass pollen allergies. But the
conditions were controlled well enough within a chal-
lenge chamber that we believe that the exacerbations
were genuine and that the results can be extrapolated to
pediatric AD patients as well. The relative significance of
exacerbating factors for AD is known to differ depend-
ing on the patient’s age, and exposure to aeroallergens,
including house dust mites, pets, and pollen, increases
the severity of AD in school age children [33].
Of the environmental allergens that AD patients are
sensitized to, house dust mites (HDM) are widely ac-
cepted as the most common in AD patients [29]. The
majority of clinical trials looking into SIT as a potential
treatment for AD focus solely on HDM SIT [29, 34].
There are currently very few studies that have looked
into the efficacy of SIT as a treatment modality for chil-
dren with AD, and there is conflicting data among them.
Arguably, the best designed of these studies was a ran-
domized, double blind, placebo controlled trial con-
ducted by Pajno et al. Their inclusion criteria did allow
for the patients to be sensitized to pollen or food aller-
gens, but they ruled out any patient with a clinically sig-
nificant allergy to anything other than HDM [15]. After
their 18-month trial period, there was significant im-
provement in both the standardized clinical severity
scoring system for AD (SCORAD) and in the use of res-
cue medication in the active sublingual immunotherapy
(SLIT) group when compared to the placebo control.
However, upon further analysis, when the subjects were
divided between mild/moderate AD and severe AD, a
statistically significant difference was only seen in the
mild/moderate group and not in the severe group, com-
pared to the placebos. Atopy and IgE sensitization ap-
pear to play a larger role in severe AD cases [17]. The
inability to show efficacy of SIT for children with severe
AD is a major detractor from its possible use as a treat-
ment modality moving forward. Two of the other
pediatric HDM SIT studies, one focusing on SLIT [35]
and the other on Subcutaneous SIT (SCIT) [36] showed
no significant clinical benefit. In one of these trials a sec-
ond study was done using the initial treatment group,
which did show significant improvement after the first
8-month trial. In this follow up study, however, the n
was reduced, making the study underpowered and the
trial became unblinded in order to continue studying the
treatment group [36]. Both studies that showed no stat-
istical difference between SIT and control also showed
surprising improvement in the control groups, one being
a placebo and the other just standard AD treatment [35,
36]. One final study that had an entirely pediatric popu-
lation, that is often cited, was actually investigating the
effects of HDM SIT on children with asthma, however
there were subjects with AD, and although there was a
subjective improvement in AD symptoms, it was not sta-
tistically significant [37].
More SIT studies focused on pediatric AD are needed to
either prove reproducibility of positive results or to defini-
tively deny its efficacy. Although HDM has garnered the
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most attention for pediatric AD SIT and shows the most
promise in the adult AD population, without an investiga-
tion into other common environmental and food aller-
gens, it is difficult to recommend SIT as a treatment
option for children with AD [34]. Other limitations to the
current studies include a lack of a standardized regimen of
treatment leading to heterogeneity between the trials mak-
ing any kind of meta-analysis of these smaller pediatric
trails impossible.
Future perspectives for studies on the specific
immunotherapy for children with AD
Without an established biomarker to attempt to predict
the outcome of treatment before it has begun, it will re-
main difficult to know which patients within the
pediatric population could benefit from SIT. Currently
only pediatric AD patients with IgE hypersensitivity,
confirmed by questionable tests, have been investigated
without producing definitive results. All of the current
literature is relying on IgE and has not produced encour-
aging results, but the answer may lie elsewhere. One
study of SIT in pollen allergies shows that a ratio of
IgG4 to IgG1 can be used to predict outcomes better
than IgE [38]. While another randomized controlled trial
of SIT in AD patients, though not limited to children,
showed no change in IgE, but saw a significant increase
in IgG4 levels [39]. Attempting to focus so specifically
on one potential allergic exacerbation of AD such as
HDM, without a better understanding of the role that al-
lergens play in the complex pathophysiology of AD does
not seem propitious at this time.
Problems of allergen-specific immunotherapy for children
with AD
Some final disadvantages to SIT are the low adherence
due to time, cost, side effect profile, and difficulty in the
route of administration. Immunotherapy has been
proven to be a safe treatment method, but it still carries
certain risks. SCIT has a higher potential for systemic
reactions than SLIT. A 10-year retrospective analysis of
general safety of SCIT showed that 5.2 % of patients ex-
perienced a systemic allergic reaction in response SCIT
injections [5]. Most of the systemic reactions were mild,
with another study estimating that a severe systemic re-
action occurs between .002 and .0076 % of injections [5].
Despite being small, adverse event rates are not negli-
gible, especially when considering that these therapies
are often administered weekly and recommended to last
up to 3 years to obtain the ideal effects. SLIT is tolerated
better, with fewer adverse events, than SCIT; gastrointes-
tinal side effects are more common than in SCIT. The
most common adverse effect of SLIT is a local mucosal
reaction, including swelling, pruritus, or dysesthesia,
which may occur in up to 75 % of all patients [5]. This
type of reaction most commonly occurs during the initi-
ation period of a SLIT regimen and usually subsides
within 1 to 3 weeks of starting the treatment. These re-
actions could promote noncompliance in patients. In
one of the few studies investigating the compliance of
SLIT in children, a population under 6 years old 46 % of
patients discontinued therapy due to a combination of
mild, localized adverse events, and the discomfort and/
or the difficulty of the route of administration [40]. With
SCIT, the patient is required to wait in the providers’
care following dose administration in order to rule out a
systemic reaction, which often occur within the first
30 min. This waiting period presents an added burden
to the patient but is necessary to ensure overall safety.
Although systemic reactions are rarer in SLIT, there is
the added risk of delayed treatment since the patient
would not be under direct observation of a healthcare
provider at the time of the event.
Conclusion
The summary of the data at present does not warrant
the use of SIT in children with AD. While we keep an
open mind, problems with selection of the appropriate
treatment population, how we handle false positive reac-
tions, and the concerns that polysensitization make it
very difficult to interpret what is clinically significant,
warrant more studies before SIT can be generally recom-
mended. Also, the potential for the misdirection of time
and energy away from skin directed therapy could nega-
tively impact on AD outcomes.
Abbreviations
AD: Atopic Dermatitis; AR: Allergic Rhinitis; FA: Food Allergy; HDM: House
Dust Mite; PPV: Positive Predictive Value; SCIT: Subcutaneous
Immunotherapy; SIT: Specific Immunotherapy; SLIT: Sublingual
Immunotherapy; SPT: Skin Prick Testing.
Competing interests
Neither of the authors have any competing of interest to disclose.
Authors’ contributions
LE conceived the primary content of the manuscript, critically revised the
drafts for content and accuracy, and gave approval for the final copy
submitted. DG performed the literature review and composed the
manuscript drafts. Both authors read and approved the final manuscript.
Author details
1Department of Dermatology, Rady Children’s Hospital, San Diego, CA, USA.
2Department of Dermatology, University of California, San Diego, La Jolla, USA.
3Division of Dermatology, Rady Children’s Hospital, San Diego, CA, USA.
Received: 17 September 2015 Accepted: 17 March 2016
References
1. Bieber T. Atopic Dermatitis. Ann Dermatol. 2010;22(2):125.
2. Hogan MB, Peele K, Wilson NW. Skin Barrier Function and Its Importance at
the Start of the Atopic March. J Allergy. 2012;2012:901940.
3. Irvine AD, McLean WH, Leung DY. Filaggrin Mutations Associated with Skin
and Allergic Diseases. N Engl J Med. 2011;365(14):1315–27.
4. Suárez-Fariñas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman SC,
et al. Intrinsic Atopic Dermatitis Shows Similar TH2 and Higher TH17
Ginsberg and Eichenfield World Allergy Organization Journal  (2016) 9:16 Page 4 of 5
Immune Activation Compared with Extrinsic Atopic Dermatitis. J Allergy Clin
Immunol. 2013;132(2):361–70.
5. Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P, et al. Guideline on
Allergen-specific Immunotherapy in IgE-mediated Allergic Diseases. Allergo
J Int Allergo. 2014;23(8):282–319.
6. Sicherer SH, Wood RA. Allergy Testing in Childhood: Using Allergen-Specific
IgE Tests. Pediatrics. 2011;129(1):193–7.
7. Pastorello EA, Incorvaia C, Ortolani C, Bonini S, Canonica GW, Romagnani S,
et al. Studies on the Relationship between the Level of Specific IgE
Antibodies and the Clinical Expression of Allergy: I. Definition of Levels
Distinguishing Patients with Symptomatic from Patients with Asymptomatic
Allergy to Common Aeroallergens. J Allergy Clin Immunol. 1995;96(5):580–7.
8. Ricci G, Patrizi A, Baldi E, Menna G, Tabanelli M, Masi M. Long-term
Follow-up of Atopic Dermatitis: Retrospective Analysis of Related Risk
Factors and Association with Concomitant Allergic Diseases. J Am Acad
Dermatol. 2006;55(5):765–71.
9. Flohr C, Johansson SG, Wahlgren CF, Williams H. How Atopic Is Atopic
Dermatitis? J Allergy Clin Immunol. 2004;114(1):150–8.
10. Yang H, Xiao YZ, Luo XY, Tan Q, Wang H. Diagnostic Accuracy of Atopy
Patch Tests for Food Allergy in Children with Atopic Dermatitis Aged Less
than Two Years. Allergol Immunopathol (Madr). 2014;42(1):22–8.
11. Bergmann MM, Caubet JC, Boguniewicz M, Eigenmann PA. Evaluation of
Food Allergy in Patients with Atopic Dermatitis. J Allergy Clin Immunol
Pract. 2013;1(1):22–8.
12. Darsow U, Vieluf D, Ring J. Evaluating the Relevance of Aeroallergen
Sensitization in Atopic Eczema with the Atopy Patch Test: A Randomized.
Double-blind Multicenter Study. JAAD. 1999;40(2):187–93.
13. Fatteh S, Rekkerth DJ, Hadley JA. Skin Prick/puncture Testing in North
America: A Call for Standards and Consistency. Allergy, Asthma Clin
Immunol. 2014;10(1):44.
14. Schäfer T. The impact of allergy on atopic eczema from data from
epidemiological studies. Curr Opin Allergy Clin Immunol. 2008;8(5):418–22.
15. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, et al.
Sublingual Immunotherapy in Mite-sensitized Children with Atopic
Dermatitis: A Randomized, Double-blind. Placebo-controlled Study. J Allergy
Clin Immunol. 2007;120(1):164–70.
16. Laske N, Niggemann B. Does the Severity of Atopic Dermatitis Correlate
with Serum IgE Levels? Pediatr Allergy Immunol. 2004;15(1):86–8.
17. Schäfer T, Heinrich J, Wjst M, Adam H, Ring J, Wichmann HE. Association
between Severity of Atopic Eczema and Degree of Sensitization to
Aeroallergens in Schoolchildren. J Allergy Clin Immunol. 1999;104(6):1280–4.
18. Depner M, Ege MJ, Genuneit J, Pekkanen J, Roponen M, Hirvonen MR,
et al. Atopic Sensitization in the First Year of Life. J Allergy Clin
Immunol. 2013;131(3):781–8.
19. De Benedictis FM, Franceschini F, Hill D, Naspitz C, Simons FER, Wahn U, et
al. The Allergic Sensitization in Infants with Atopic Eczema from Different
Countries. Allergy. 2009;64(2):295–303.
20. Bath-Hextall F, Delamere FM, Williams HC. Dietary Exclusions for Improving
Established Atopic Eczema in Adults and Children: Systematic Review.
Allergy. 2009;64(2):258–64.
21. Sicherer SH. Food Allergy: When and How to Perform Oral Food Challenges.
Pediatr Allergy Immunol. 1999;10.4:226–34.
22. Werfel T, Ballmer-Weber B, Eigenmann PA, Niggemann B, Rancé F,
Turjanmaa K, et al. Eczematous Reactions to Food in Atopic Eczema:
Position Paper of the EAACI and GA2LEN. Allergy. 2007;62(7):723–8.
23. Illi S, von Mutius E, Lau S, Nickel R, Grüber C, Niggemann B, et al. The
Natural Course of Atopic Dermatitis from Birth to Age 7 Years and the
Association with Asthma. J Allergy Clin Immunol. 2004;113(5):925–31.
24. Du Toit G, Roberts G, Sayre PH, Plaut M, Bahnson HT, Mitchell H, et al. Identifying
Infants at High Risk of Peanut Allergy: The Learning Early About Peanut Allergy
(LEAP) Screening Study. J Allergy Clin Immunol. 2013;131(1):135–43.
25. Werfel T, Breuer K. Role of Food Allergy in Atopic Dermatitis. Curr Opin
Allergy Clin Immunol. 2004;4(5):379–85.
26. Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis:
pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin
Immunol. 1999;104:S114–22.
27. Silverberg JI, Simpson EL. Association between severe eczema in children
and multiple comorbid conditions and increased healthcare utilization.
Pediatr Allergy Immunol. 2013;24:476–86.
28. Burks AW, Mallory SB, Williams LW, Shirrel MA. Atopic dermatitis: Clinical
relevance of food hypersensitivity reactions. J Pediatr. 1988;113:447–51.
29. Lee J, Park CO, Lee KH. Specific Immunotherapy in Atopic Dermatitis.
Allergy, Asthma Immunol Res. 2015;7(3):221–9.
30. Jones SM, Burks AW, Dupont C. State of the Art on Food Allergen
Immunotherapy: Oral, sublingual, and Epicutaneous. J Allergy Clin
Immunol. 2014;133(2):318–23.
31. Boyce JA, Assa’ad A, Burks AW, Jones SM, Sampson HA, Wood RA, et al.
Guidelines for the diagnosis and management of food allergy in the United
States: summary of the NIAID-Sponsored Expert Panel report. J Am Acad
Dermatol. 2011;64:175–92.
32. Werfel T, Heratizadeh A, Niebuhr M, Kapp A, Roesner LM, Karch A, et al.
Exacerbation of Atopic Dermatitis on Grass Pollen Exposure in an
Environmental Challenge Chamber. J Allergy Clin Immunol. 2015;136(1).
33. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann
P, et al. Diagnosis and Treatment of Atopic Dermatitis in Children and
Adults: European Academy of Allergology and Clinical Immunology/
American Academy of Allergy, Asthma and Immunology/PRACTALL
Consensus Report. J Allergy Clin Immunol. 2006;118:152–69.
34. Bussmann C, Bockenhoff A, Henke H, Werfel T, Novak N. Does Allergen-
specific Immunotherapy Represent a Therapeutic Option for Patients with
Atopic Dermatitis? J Allergy Clin Immunol. 2006;118(6):1292–8.
35. Galli E, Chini L, Nardi S, Benincori N, Panei P, Fraioli G, et al. Use of a specific
oral hyposensitization therapy to Dermatophagoides pteronyssinus in children
with atopic dermatitis. Allergol Immunopathol (Madr). 1994;22:18–22.
36. Glover MT, Atherton DJ. A Double-blind Controlled Trial of
Hyposensitization to Dermatophagoides Pteronyssinus in Children with
Atopic Eczema. Clin Exp Allergy. 1992;22(4):440–6.
37. Warner JO, Price JF, Soothill JF, Hey EN. Controlled Trial Of Hyposensitisation
To Dermatophagoides Pteronyssinus In Children With Asthma. Lancet. 1978;
312(8096):912–5.
38. Gehlhar K, Schlaak M, Becker W, Bufe A. Monitoring Allergen
Immunotherapy of Pollen-allergic Patients: The Ratio of Allergen-specific
IgG4 to IgG1 Correlates with Clinical Outcome. Clin Exp Allergy. 1994;29(4):
497–506.
39. Sánchez Caraballo JM, Cardona Villa R. Clinical and Immunological Changes
of Immunotherapy in Patients with Atopic Dermatitis: Randomized
Controlled Trial. ISRN Allergy. 2012:1–9.
40. Pajno GB, Caminiti L, Crisafulli G, Barberi S, Landi M, Aversa T, et al.
Adherence to sublingual immunotherapy in preschool children. Pediatr
Allergy Immunol. 2012;7:688–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ginsberg and Eichenfield World Allergy Organization Journal  (2016) 9:16 Page 5 of 5
